Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca’s Farxiga fails to receive U.S. approval for type 1 diabetes

The U.S. Food and Drug Administration declined to approve AstraZeneca Plc’s diabetes treatment Farxiga for use as a supplement to insulin in adults with a rare type of the condition.

Read More »

New Insights into the Vagus Nerve Could Change the Way Diabetes is Treated

A new discovery at the Feinstein Institutes for Medical Research could have implications in the way diabetes is treated in the future.

Read More »

U.S. aims to cut dialysis in centers, increase transplants by 2025

The Trump administration plans to change the way it pays for kidney disease treatments to favor lower cost care at home and transplants over the current standard, dialysis clinics, top health officials said during a press briefing.

Read More »

Weightlifting better at reducing heart fat than aerobic exercise

Obese people who engaged in resistance training were more likely to see reductions in a type of heart fat, a new study finds.

Read More »

Most older adults with ‘prediabetes’ don’t develop diabetes

Older adults with slightly elevated blood sugar – sometimes called “prediabetes” – usually do not develop full-blown diabetes, a Swedish study suggests.

Read More »

Varied bedtimes tied to obesity, diabetes, high blood pressure

People who do not consistently get the same amount of sleep or go to bed at the same time each night may be more likely to develop health problems like obesity, high blood pressure, high cholesterol and diabetes, a recent study suggests.

Read More »

Trulicity Shows Superiority in Reducing Weight, A1C

Lilly’s diabetes drug Trulicity hit the mark in a late-stage trial showing higher doses of the medication significantly reduced A1C from baseline versus the product’s approved once-weekly usage.

Read More »

Novo Nordisk Wins Expanded Approval for Victoza

Novo Nordisk’s diabetes drug Victoza (liraglutide) earned approval from the U.S. FDA for an expanded indication for use in children ages 10 to 17 years who have type 2 diabetes.

Read More »

Abbott Launches First-ever Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes

Abbott’s Afinion HbA1c Dx assay was launched as the only rapid point-of-care test cleared by the U.S. Food and Drug Administration to aid healthcare professionals in the diagnosis of diabetes and the assessment of patients’ risk of developing the condition.

Read More »

ADA Spotlight: Novo Nordisk, Boehringer Ingelheim, Eli Lilly and More

Almost 15,000 physicians, scientists, health-care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association (ADA)’s 79th Scientific Sessions in San Francisco.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom